Small Pharma (DMT) Stock Price, News & Analysis

Company Overview

Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage. Its preclinical stage programs include SPL029, an oral formulation of a tryptamine to treat depressive disorder. The company is headquartered in London, the United Kingdom. As of October 23, 2023, Small Pharma Inc. operates as a subsidiary of Cybin Inc.

Key Stats

• Today's Range: C$0.15 to C$0.16
• 50-Day Range: C$0.15 to C$0.15
• 52-Week Range: C$0.06 to C$0.22
• Volume: 1.89 million shs
• Average Volume: 296,159 shs
• Market Capitalization: C$50.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DMT Stock Analysis - Frequently Asked Questions

How have DMT shares performed this year?

Small Pharma's stock was trading at C$0.15 on January 1st, 2025. Since then, DMT shares have increased by 0.0% and is now trading at C$0.15.
View the best growth stocks for 2025 here.

How do I buy shares of Small Pharma?

Shares of DMT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Small Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Small Pharma investors own include Bombardier, Inc. Class B (BBD.B), Arrival (ARVL), Air Canada (AC), Beyond Meat (BYND), BioSig Technologies (BSGM), Aveanna Healthcare (AVAH) and Actinium Pharmaceuticals (ATNM).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:DMT
• CIK: N/A
• Web: www.smallpharma.co.uk
• Phone: 44 78 1212 1944
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-19,310,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -116.90%
• Return on Assets: -66.00%

Debt

• Debt-to-Equity Ratio: 5.95
• Current Ratio: 2.63
• Quick Ratio: 6.28

Sales & Book Value

• Annual Sales: C$-1,162.00
• Price / Sales: -43,343.80
• Cash Flow: C$0.13 per share
• Price / Cash Flow: 1.13
• Book Value: C$0.03 per share
• Price / Book: 5.00

Miscellaneous

• Outstanding Shares: 335,770,000
• Free Float: N/A
• Market Cap: C$50.37 million
• Optionable: Not Optionable
• Beta: 0.86